Style Editor Docs
     
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • US FDA IDE Process Updates
    • Human Clinical Trials
  • IsoPet®
    • IsoPet® Therapy
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • Our MIssion with IsoPet®
    • Animal Studies
      • Canine Studies
      • Feline Studies
  • About
    • Management & Consultants
    • Advisory Boards
  • Contact
  • Investors
    • Board of Directors
 (+1) 509‑736-4000,  
   Contact Us
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • US FDA IDE Process Updates
    • Human Clinical Trials
  • IsoPet®
    • IsoPet® Therapy
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • Our MIssion with IsoPet®
    • Animal Studies
      • Canine Studies
      • Feline Studies
  • About
    • Management & Consultants
    • Advisory Boards
  • Contact
  • Investors
    • Board of Directors

    RadioGel™ Cancer Therapy

    RadioGel is an Yttrium-90 based injectable Precision Radionuclide Therapy (PRnT) device
    for the treatment of cancerous tumors in animals (IsoPet®) and humans (RadioGel™).

    Precision Radionuclide Therapy (PRnT) uses highly localized radiation to destroy,
    cancerous tumors by placing a radioactive isotope directly inside the treatment
    area using the company’s proprietary hydrogel technology.


    Learn more

    RadioGel™ – Cancer therapy for humans.

    Radiogel™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.


    Learn More

    IsoPet® – Cancer therapy for animals

    The Isopet® Solutions division utilized university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. Testing on feline sarcoma at the Washington State University was completed in 2018 and testing on canine soft tissue sarcomas at the University of Missouri was completed in 2019.

    IsoPet® Therapy is readily available at The University of Missouri and select Regional Clinics.

    Learn More


    “We are continually striving to enhance and grow our Intellectual property portfolio to build value to our stakeholders and to strengthen our position as an emerging leader in precision radionuclide therapy.”

    ( Mike Korenko, Sc.D • CEO • President | May 12, 2022 Press Release )

    May 12, 2022 • Vivos Inc. Provides Intellectual Property Protection Update

    Richland WA, May 12, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it expanded its intellectual property protection on several fronts. 

     

    Our patent team filed our particle patent in more than ten patent offices that collectively cover 63 countries throughout the world. This year we also filed a provisional patent number 63-299,930 giving us broader protection on recent and projected developments on both our hydrogel and our particle components. This week we filed a continuation-in-part applications number 1774054 in the USA to expand the claims on our particle patent.

     

    We are near completion on additional development work and intend to file expanded particle claims internationally using the Patent Cooperation Treaty, PCT, process. Additionally, building on the substantial refinements to our hydrogel during the past two years, we also plan to file a new utility patent to protect these proprietary developments. We anticipate the filings will be completed during the third quarter.

     

    In closing Dr. Korenko stated, “We are continually striving to enhance and grow our Intellectual property portfolio to build value to our stakeholders and to strengthen our position as an emerging leader in precision radionuclide therapy.”

    Home Page Cover Image: 

     

    Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.

     

    Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.

    RadioGel™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

    IsoPet® Therapy Application(s)


    Precision Radionuclide Therapy (PRnT)


    Vivos Inc.
     - (OTCQB:RDGL) Investor Relations 

    Contact

     

    Main colors
       bg-primary
       bg-primary-light
       bg-primary-dark
       bg-secondary
       bg-secondary-dark
    Template sections
       body
       top-header
       header
       content
    Footer Styles
       background
       text color
       link color
       horizontal line
    Buttons
       style 1
       style 2
       style 3
    Other elements
      social icons
      navigation color
      subnav background
    Mobile navigation
       background color
       navigation color
    Template configurations
    has-right-nav g-font
    navigation styles
    size-15 weight-400 snip-nav
    content styles
    form-white
    footer styles
    o-form color-white
    Typography
    Heading H1
    weight-600
    Heading H2
    weight-600
    Heading H3
    weight-600
    Buttons
    weight-600 is-uppercase
    Animations

    Note:
    All changes made here will be applied to your entire website.
    is-switcher admin-only

    draggable-logo

    About | Privacy Policy | Cookie Policy | Sitemap
    © 2022 Vivos Inc. | RadioGel™ is a registered trademark | IsoPet® is a registered trademark
    Log out | Edit
    • Scroll to top